STEP-5 ( Nature Medicine , 2024) and SELECT ( Lancet , 2024) showed sustained appetite suppression and metabolic benefit for up to two years without diminishing drug response
(2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
If youre following weight loss medications, retatrutide is worth tracking, and Phase 3 results over the next few years will tell us whether the early promise holds
Once youve found the dosage that works for you, bundling is highly recommended, as you can save up to 35%
Pratique et facile utiliser, il se dissout facilement dans de leau, offrant une solution agrable pour intgrer un soin de la peau au quotidien